46
Participants
Start Date
January 31, 2012
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
RAD001 + BEZ235
RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
Novartis Investigative Site, Wilrijk
Medical University of South Carolina SC, Charleston
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Montellier Cedex 5
Novartis Investigative Site, Verona
Washington University School of Medicine Washington University (16), St Louis
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville
Novartis Investigative Site, Auckland
Novartis Investigative Site, Barcelona
Novartis Investigative Site, High Heaton
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY